Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.110 -0.040 (-0.56%)
Streaming Delayed Price Updated: 9:31 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
41 42 Next >
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 2.08% at $0.49 
Via Benzinga
Allied, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 6.17% at $3.44 
Via Benzinga
Psychedelic Stock Gainers And Losers From September 28, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 10.48% at $1.16 
Via Benzinga
Biomind Labs, Allied Among Top Psychedelic Movers Of Today
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 11.10% at $1.10 
Via Benzinga
Study Finds Using Social Media May Negatively Affect Youths’ Mental Health
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
Via Investor Brand Network
Topics Intellectual Property
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. 
Via Benzinga
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
From Cybin Inc.
Via Business Wire
Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.91% at $0.13 
Via Benzinga
The 5 Cannabis Categories Fell Even Further Last Week
The 5 categories in the cannabis sector performed quite differently from each other again last week. The ones that lost least are the most peripheral to the growing and/or distribution of cannabis. 
Via Talk Markets
Psychedelic Stocks Continue To Plummet: -16% This Week; -33% MTD; Now -57% YTD
Look at how the only psychedelic stocks with market caps larger than $50M gave performed this last week. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From September 22, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.80% at $1.10 
Via Benzinga
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one... 
Via FinancialNewsMedia
Psychedelic Stock Gainers And Losers From September 21, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.87% at $0.32 
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences
Via Investor Brand Network
Cybin to Participate in Upcoming Scientific and Investor Conferences
From Cybin Inc.
Via Business Wire
Seelos Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 7.83% at $0.62 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe
Via Investor Brand Network
Hamilton Morris Confirmed as Keynote Speaker at Convergence Psychedelic Conference
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose
Via Investor Brand Network
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From September 19, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.28% at $0.65 
Via Benzinga
The 5 Cannabis Categories Declined Between 3% And 11.5% Last Week
The cannabis sector consists of 5 distinctly different categories and they each perform quite differently. 
Via Talk Markets
8 Largest Psychedelic Stocks Continued Their Decline Last Week
The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index were collectively down 10% in the past week. We also take a look at some therapy-clinic stocks. 
Via Talk Markets
Numinus Wellness, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 3.98% at $14.64 
Via Benzinga
Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
Via Investor Brand Network
GH Research, Cybin Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 9.26% at $13.81 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
Via Investor Brand Network
Study Finds Hepatitis C Drugs May Help Alleviate Symptoms of PTSD
Via Investor Brand Network
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.